| http://www.w3.org/ns/prov#value | - The incidence of overall adverse effects in patients taking neuraminidase inhibitors was 37.6 percent versus 18 percent in the placebo group (OR, 2.59; 95 percent CI, 1.59 to 4.21).2 Asthma is a contraindication to the use of zanamivir because the latter may induce bronchospasms.6
|
